Anbio Biotechnology (NASDAQ:NNNN) Sees Large Growth in Short Interest

Anbio Biotechnology (NASDAQ:NNNN) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 58,423 shares, an increase of 122.9% from the August 15th total of 26,210 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 286,803 shares, the days-to-cover ratio is currently 0.2 days.

Anbio Biotechnology Stock Down 9.8%

Shares of Anbio Biotechnology stock traded down $0.60 during trading hours on Tuesday, reaching $5.51. 274,992 shares of the company were exchanged, compared to its average volume of 71,945. The stock’s fifty day moving average is $8.87 and its 200 day moving average is $18.60. Anbio Biotechnology has a 1 year low of $5.25 and a 1 year high of $51.33.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.